Les auteurs rapportent un cas d'état maniaque probablement favorisé par la prise de DHEA aux doses de 150-200mg/j chez un homme de 68 ans bipolaire non traité ayant déjà dans ses antécédents un état maniaque dans un contexte de deuil. La DHEA et son sulfate (S-DHEA) sont des précurseurs d'hormones sexuelles masculines et à un moindre degré féminines, produits dans les deux sexes par les surrénales. La concentration plasmatique de la DHEA varie au cours de la vie. Sa baisse avec l'âge serait responsable de la morbidité liée au vieillissement. Présentée comme une véritable pilule de jouvence susceptible de prévenir les pathologies liées à l'âge, d'améliorer la sexualité mais aussi la symptomatologie dépressive, très largement utilisée aux USA, elle fait l'objet, en France, d'une demande en forte expansion mais n'a pas reçu d'autorisation de mise sur le marché en tant que médicament. Peu d'informations concernent donc l'efficacité, les interactions, et les effets de l'utilisation à long terme comme du sevrage brutal de ce produit.

Dehydroepiandrosterone (DHEA) and its sulfate ester metabolite (DHEA-S) are precursors to testosterone and, to a lesser extent, to estrogen, and, for both sexes, they are produced in the adrenal cortex. They are among the most abundant steroids in the human body, yet their physiological roles remain unknown. DHEA and DHEA-S appear to have diverse biochemical activities, including actions within the central nervous system. So DHEA is produced in the central nervous system as well as the human adrenals and is present in the brain, concentrated in limbic regions, in levels much higher than other steroids. DHEA has been postulated to function as an excitory neuroregulator, antagonizing g-aminobutyric acid transmission. The main characteristic of DHEA is that its level of concentration in plasma varies throughout life, such level being low during the early childhood and after the age of 60 years. Adrenal production and serum concentrations of DHEA are then known to peak between ages 25 and 30 years and thereafter decrease with age, severe illness and chronic stress. The decrease of DHEA over time would appear to be responsible for morbidity related to aging process. Previous reports have found low levels of DHEA in association with physical and with frailty in the elderly (immunosenescence, increased incidence of osteoporosis, atherosclerosis and cancer, decreased cognitive functions and/or well-being). As it has been touted as a fountain of youth and a sexual tonic and promoted for a variety of illnesses associated with aging, DHEA is widely available over all the United States (since 1994) as a dietary supplement. In France, as a result of a massive advertising campaign, DHEA is already the subject of a widespread use and a growing demand although it has not yet been approved by the relevant authorities for sale as drug to the public. In practice, DHEA is prescribed and delivered under the sole responsibility of both doctor and chemist who ascertain the benefit-risk ratio and the quality of the product. DHEA may then be purchased on the internet or in the form of magistral preparations delivered on the basis of such prescription. Accordingly, there is little information or data on efficacy, drug interactions, results of long-term use, abrupt discontinuation or potential adverse effects related to the use of DHEA. We report a case of mania possibly precipitated by the use of high doses of DHEA (150-200 mg/day at the time of presentation) during several weeks in a 68 years old man who had already been hospitalized for an acute mania many years ago. Although, in this case, the patient suffered a bipolar diathesis in the past, oral DHEA may have played a role in the induction of his acute manic episode. Further research is required to assess the mood effects of DHEA, including its potential risk for patients with bipolar disorder.